-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprea Therapeutics To Present Updated Results From Ongoing Phase 1 ACESOT-1051 Trial Of APR-1051, Investigational, Oral, Selective WEE1 Inhibitor, At 38th EORTC-NCI-AACR Symposium

Benzinga·11/20/2026 14:03:36
Listen to the news

Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development 

Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration

Planned expansion into focused cohorts in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, where WEE1 inhibition may be most therapeutically relevant

DOYLESTOWN, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. Interim results will be presented today in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, by Timothy A. Yap, MBBS, PhD, FRCP, of The University of Texas MD Anderson Cancer Center, the lead investigator of the study. As of the November 1, 2026 cut off date, 56 patients had received APR-1051 across all dose levels. The interim dataset includes one confirmed (on treatment for more than 10 months at cutoff) and one unconfirmed RECIST 1.1 partial response in patients with PPP2R1A-mutated uterine cancers and five patients with stable disease lasting more than four months. Pharmacodynamic evidence of WEE1 target engagement across multiple dose levels, together with the safety profile and longer follow-up on previously reported clinical activity, support continued dose optimization and continuous once-daily administration. Aprea plans to enroll at least 50 patients with uterine serous carcinoma (USC) or cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC), as dose escalation and backfill expansion enrollment continue, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of 2027.